In Q2 2023, Cormorant Asset Management held 43 positions worth $1.4B. They initiated 8 new positions and exited 14. Their largest holding was MLTX ($415.2M). Portfolio value grew +16.0% versus the prior quarter.
Frequently asked questions
What stocks did Cormorant Asset Management own in Q2 2023?
Cormorant Asset Management held 43 biotech stocks in their 13F portfolio in Q2 2023. Their top positions include MLTX, APLS, BMEA, BBIO, ACLX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Cormorant Asset Management's portfolio worth in Q2 2023?
Cormorant Asset Management's tracked biotech portfolio was worth $1.4B across 43 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Cormorant Asset Management buy in Q2 2023?
Cormorant Asset Management initiated 8 new positions in Q2 2023, including ZNTL, PRAX, IMVT, IRON, RYTM and 3 more. They also increased 11 existing positions.
What did Cormorant Asset Management sell in Q2 2023?
Cormorant Asset Management fully exited 14 positions in Q2 2023, including XFOR, VKTX, TNGX, PYXS, RXDX and 9 more. They also trimmed 4 existing positions.
Is Cormorant Asset Management a biotech fund?
Healthcare-focused crossover fund that invests from late-stage private through public markets. Known for concentrated, high-conviction positions in clinical and commercial-stage biotech companies with strong scientific differentiation.
Want AI analysis, insider signals, and catalyst overlays for Cormorant Asset Management?
View latest Cormorant Asset Management portfolio →